Keyword: Aerie Pharmaceuticals
The appointment puts Vargas in charge of medical affairs organizational planning and operational matters at the eye disease company.
A Yale University team found two potential methods for preventing fat particles from slipping into tissues.
Former Ariad CEO leads Roivant and Arbutus' new RNA JV, Purdue Pharma names new R&D head, Immunomedics poaches AZ I-O exec as R&D chief.
Vik Bajaj left Grail as CSO, Aerie lured Allergan medical affairs veteran Maltman, AMRI poached Mylan’s M&A expert Feuerman.
Maltman joins the fast-hiring eye disease specialist three months after taking up a vice president position at Allergan.
The FDA agreed with the efficacy conclusion Aerie reached to support its bid for approval of glaucoma and ocular hypertension hopeful Rhopressa.
Andrew Witty jumped into biotech venture capital, Aerie poached another exec from Alcon, Roivant tapped Silicon Valley vet to run trial AI company.
Eric Carlson, Ph.D., has become the latest in a string of former Alcon employees to land at the smaller eye disease specialist.
Aerie Pharma—just months away from a possible approval for its lead glaucoma drug—is hoping to unlock the potential of a key pipeline compound with help from Netherlands company Royal DSM.
